anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
An appropriate hypothalamic-pituitary-adrenal (HPA) axis response is required to survive critical illness. Primary adrenal insufficiency, relative adrenal insufficiency, tissue resistance to glucocorticoids, ACTH deficiency and immune-mediated inhibition of the HPA axis may impair the secretion or action of glucocorticoids in critically ill patients. Adrenal insufficiency is estimated to occur in up to 77 percent of critically ill patients, but currently, there is no consensus on the diagnostic criteria for adrenal insufficiency in this setting, and standard testing does not discriminate among the aforementioned factors. We will study the incidence and natural history of adrenal insufficiency in critically ill patients to further define adrenal insufficiency and provide data to develop diagnostic tests. Clinical features and outcomes will be correlated with laboratory measurements of hormones, cytokines and glucocorticoid action. Healthy volunteers will undergo cortrosyn tests with measurement of free cortisol levels to develop a normative range for this endpoint. Patients with known adrenal insufficiency will also be studied to help determine the clinical utility of diagnostic tests among these different groups. Previous glucocorticoid use, if prolonged and supraphysiologic, also inhibits the HPA axis and can result in adrenal insufficiency. Patients with short intermittent courses of glucocorticoid administration have not been studied well, and may also be at risk. To gain further information about this group, patients receiving pulse glucocorticoid doses as part of bone marrow transplant regimens at the Clinical Center will also be studied.
In postmarketing spontaneous reports, there have been cases of medication errors in which the entire contents (up to 800 mcg) (40 times the recommended dose) of the teriparatide injection prefilled delivery device (pen) have been administered as a single dose. Transient events reported have included nausea, weakness/lethargy and hypotension. No fatalities associated with overdose have been reported. Additional signs, symptoms, and complications of teriparatide injection overdosage may include a delayed hypercalcemic effect, vomiting, dizziness, and headache. 

Overdose Management — There is no specific antidote for a teriparatide overdosage. Treatment of suspected overdosage should include discontinuation of teriparatide injection, monitoring of serum calcium and phosphorus, and implementation of appropriate supportive measures, such as hydration.
The aim of this proposal is to improve our understanding of factors related to brain health and cognition of school-aged children by examining the effects of a 9-month exercise intervention on basic and applied aspects of cognition in preadolescent children. From a basic measurement perspective, event-related brain potentials, MRI, fMRI, and behavioral indices of cognition will be studied during several tasks aimed at assessing various aspects of executive control. Preliminary research has observed faster and more efficient performance in high-fit, relative to low-fit, children and adults using neuroelectric measures that reflect attentional allocation to environmental stimuli and response monitoring processes, along with behavioral measures that reflect response speed and accuracy. These preliminary findings indicate greater top-down attentional control may be associated with increases in physical activity. From an applied measurement perspective, preliminary research has found that children with greater aerobic fitness perform better on standardized achievement tests of reading and mathematics, compared to children with lower aerobic fitness, suggesting that exercise may be related to academic performance in an applied school setting. To date, no causal evidence exists regarding the effects of physical activity on neuroelectric, behavioral, or applied school performance indices of cognition in children. Accordingly, this proposal investigates an aerobic activity training intervention on these measures of cognition using three tasks that require variable amounts of executive control, and on the Illinois Standardized Achievement Test using a randomized control design in which participants are assigned to an afterschool physical activity program or a wait-list control group. Given recent trends identifying decreased levels of physical activity and health status in preadolescents, the understanding of the potential benefits of physical activity on cognition is of great interest. It is imperative that factors positively influencing cognitive function of children be examined to maximize health and effective functioning of individuals as they progress through the lifespan.
A therapeutic preparation for the treatment of allergic affections such as asthma and rheumatism is obtained by preparing a culture medium from meat broth, human blood or plasma and glucose, wherein prior to the addition of the human blood or plasma and glucose the broth is mixed with sodium chloride and bacteriological peptone. neutralized with a solution of sodium carbonate and heated at a temperature of about but not exceeding 125 DEG  C. and the precipitate formed removed, the culture medium then being inoculated with at least two species of bacteria belonging to the groups staphylococcus, streptococcus, pneumococcus and micrococcus catarrhalis of preferably different genus and causing the bacterial metabolism to proceed until substantially all the nutritious substances of the culture medium are consumed.  After said heat step glucose is added to the cooled broth, e.g. in a concentration of 2 per cent by volume, followed by vitamins and inorganic salts, the pH is adjusted to 6.8 to 7.2 and then sterilized at 110-115 DEG  C. After cooling, hemolized human blood in sterile water is added and the medium so formed inoculated with the above micro-organisms. Cultivation is at 38-38.5 DEG  C. for 3 to 4 days with agitation and, if necessary, with further inoculation of the bacteria.  A solution of phenol in camphor is added and the product filtered, lyophilized or filled into vials.  Specified vitamins and mineral salts are streptogenin, pantothenic acid, biotin, nicotinamide, pyridoxine, aneurin, magnesium sulphate, ferrous sulphate, cobalt sulphate, manganese sulphate, zinc sulphate, copper sulphate, sodium molybdate and potassium iodide.
PURPOSE: Cosmetics including a screen net is provided to prevent the change of feeling of touch with the passage of time, thereby giving freshness like using a new product. CONSTITUTION: Cosmetics including a screen net (10) comprises: the screen net having one or more materials selected from the group consisting of polyurethane, thermoplastic elastomer (TPE), polyester, polyether, acryl, and olefin; and an absorbent adjacent to the screen net. The size of the hole of the screen net is 0.01-1.0 mm. The extension rate is 1-100% when the force is applied to the unit area of 1cm2 of the screen net in upward and downward directions. The force applied to the screen net in upward and downward directions is 400g.f to 1kg.f. The screen net has an edge (20) surrounding the screen net. The absorbent adheres to the screen net or positioned 0.1-3.0 mm away. A manufacturing method of the cosmetics comprises: a step of absorbing the liquid content into the absorbent; and a step of adjoining the absorbent and the screen net.
Once the PVI block is confirmed, a figure-of-eight suture is placed at the femoral access site. The sheaths are removed and haemostasis should be achieved by manual compression at the discretion of the operator. Protamine may be administered according to institutional standards. A tourniquet is applied for a minimum of 30 minutes and the patient should remain supine.
PURPOSE:To obtain a cholesterol lowering agent, containing low-molecular weight chitosan having a molecular weight within a specific range as an active ingredient, having high cholesterol lowering effects, providing high effects with a small amount thereof used, capable of exhibiting a low viscosity due to a low molecular weight thereof and applicable to foods, beverages, etc. CONSTITUTION:A cholesterol lowering agent containing low-molecular weight chitosan having 2000-20000 weight-average molecular weight. The low-molecular weight chitosan preferably has more amino groups and a higher colloid equiv. value. The aforementioned low-molecular weight chitosan can readily be produced by, e.g. deacetylating chitin with an alkali and reducing the molecular weight of the resultant chitosan according to a conventional method. Since the above-mentioned chitosan has the molecular weight within the limit region solubilizing under neutral or alkaline conditions, cholesterol lowering effects are effectively exhibited by keeping a get state with excellent dispersibility. Furthermore, since the chitosan has the low viscosity in a dissolved state, addition to foods or beverages is readily carried out. Industrial usefulness of the agent is high.
The EGFR is a transmembrane glycoprotein that is a member of a subfamily of type I receptor tyrosine kinases, including EGFR, HER2, HER3, and HER4. EGFR is constitutively expressed in normal epithelial tissues, including the skin and hair follicle. EGFR is overexpressed in certain human cancers, including colon and rectum cancers. Interaction of EGFR with its normal ligands (e.g., EGF, transforming growth factor-alpha) leads to phosphorylation and activation of a series of intracellular proteins, which in turn regulate transcription of genes involved with cellular growth and survival, motility, and proliferation. KRAS (Kirsten rat sarcoma 2 viral oncogene homologue) and NRAS (Neuroblastoma RAS viral oncogene homologue) are highly related members of the RAS oncogene family. Signal transduction through the EGFR can result in activation of the wild-type KRAS and NRAS proteins; however, in cells with activating RAS somatic mutations, the RAS-mutant proteins are continuously active and appear independent of EGFR regulation.

Panitumumab binds specifically to EGFR on both normal and tumor cells, and competitively inhibits the binding of ligands for EGFR. Nonclinical studies show that binding of panitumumab to the EGFR prevents ligand-induced receptor autophosphorylation and activation of receptor-associated kinases, resulting in inhibition of cell growth, induction of apoptosis, decreased proinflammatory cytokine and vascular growth factor production, and internalization of the EGFR. In vitro assays and in vivo animal studies demonstrate that panitumumab inhibits the growth and survival of selected human tumor cell lines expressing EGFR.
This study arm consists of a fixed sequence crossover where study subjects will receive Treatment A and following a washout of no less than 10 days will then receive Treatment B. The drug class is a CDK4/6 inhibitor.
Twelve trial subjects are appointed to two subgroups that differ in the minimum wearing duration of the insert (12 month and 18 month). In Cohort 4 a new insert will be tested together with a better photometer.
Studies have shown that between one-quarter and one-half of infants undergoing cardiac surgery will suffer brain injury during surgery (the perioperative period). Some infants with congenital heart disease have neurological injury prior to cardiac surgery as a result of cyanosis, acidosis and abnormal circulation. The spectrum of neurological injury ranges from agitation and subtle disturbances in learning and new memory acquisition to visual and motor development abnormalities, seizures, stroke and encephalopathy.

The patient will be identified from the cardiothoracic surgery database. Their hospital medical records and the neurological database will be reviewed for type of neurological complication (i.e. seizure, stroke), neuro-imaging and any mortality for these patients. We will review the patient outcome data that is available, after the initial surgery, through June 20, 2006. No patients will be contacted.
Participants will have screening tests up to 4 weeks before study treatment and dosing for up to 48 weeks. Brentuximab vedotin will be given with a dose of 1.8 mg (per kilogram of participant's body weight) intravenously (an IV through their vein) every 21 days, over 30 minutes for 16 cycles. Follow-up assessments will be performed up to 104 weeks (2 years).
BACKGROUND: Sevoflurane is a superior agent for maintaining anesthesia during surgical procedures. However, the neurotoxic mechanisms of clinical concentration remain poorly understood. Sevoflurane can interfere with the normal function of neurons and synapses and impair cognitive function by acting on α5-GABAAR.
METHODS: Using MWM test, we evaluated cognitive abilities in mice following 1 h of anesthesia with 2.7%-3% sevoflurane. Based on hippocampal transcriptome analysis, we analyzed the differential genes and IL-6 24 h post-anesthesia. Western blot and RT-PCR were performed to measure the levels of α5-GABAAR, Radixin, P-ERM, P-Radixin, Gephyrin, IL-6, and ROCK. The spatial distribution and expression of α5-GABAAR on neuronal somata were analyzed using histological and three-dimensional imaging techniques.
RESULTS: MWM test indicated that partial long-term learning and memory impairment. Combining molecular biology and histological analysis, our studies have demonstrated that sevoflurane induces immunosuppression, characterized by reduced IL-6 expression levels, and that enhanced Radixin dephosphorylation undermines the microstructural stability of α5-GABAAR, leading to its dissociation from synaptic exterior and resulting in a disordered distribution in α5-GABAAR expression within neuronal cell bodies. On the synaptic cleft, the expression level of α5-GABAAR remained unchanged, the spatial distribution became more compact, with an increased fluorescence intensity per voxel. On the extra-synaptic space, the expression level of α5-GABAAR decreased within unchanged spatial distribution, accompanied by an increased fluorescence intensity per voxel.
CONCLUSION: Dysregulated α5-GABAAR expression and distribution contributes to sevoflurane-induced partial long-term learning and memory impairment, which lays the foundation for elucidating the underlying mechanisms in future studies.
Nonischemic dilated cardiomyopathy (NIDCM) is associated with an increased risk of atrial fibrillation (AF) and stroke, especially in patients with high CHA2DS2-VASc. We aimed to identify variables associated with incident AF or stroke using left atrial deformation analysis and its prognostic value added to CHA2DS2-VASc score. Patients with NIDCM and left ventricular ejection fraction <50% in sinus rhythm were included between January 2015 and December 2019. Left atrial volume index (LAVI) and atrial strain were used in combination with the CHA2DS2-VAS score to predict ischemic stroke or incident AF. Proportional hazards Cox regression was used to provide hazard ratios (HRs). There were 338 patients included. After a median follow-up of 3.6 years, the end point occurred in 41 patients (12.1%). LAVI outperformed other echocardiographic parameters, with a significant improvement in risk reclassification compared with CHA2DS2-VASc alone (net reclassification index 0.6, increase in Harrell's C from 0.63 to 0.73, p = 0.003), and remained significant after multivariate adjustment. LAVI was associated with both components of the end point separately. The best cutoff for LAVI was 44 ml/m2. LAVI ≥44 ml/m2 increased the risk of the end point among those with CHA2DS2-VASc ≥3 (HR 6.0, 95% confidence interval 2.6 to 13.5) but not in those with CHA2DS2-VASc <3 (HR 1.2, 95% confidence interval 0.3 to 4.5). Competing risk analysis did not alter the results. In conclusion, LAVI might be used to assess the risk of incident AF or stroke in NIDCM. Patients with LAVI ≥44 ml/m2 and CHA2DS2-VASc ≥3 could be at high risk of AF and stroke and may benefit from more intensive surveillance.
In preparing a chewing composition or pastilles, troches, lozenges, "drops" &c. to be dissolved in the mouth, there is incorporated in the composition a therapeutically active sulpha drug and a non-toxic solubilising agent for the drug consisting of an alkaline alkali metal compound or an alkaline calcium compound. Specified sulpha drugs are sulphadiazine, sulphamerazine, sulphapyridine, sulphanilamide, "Prontosil" (Registered Trade Mark), "Uleron" (Registered Trade Mark), sulphathiazole, sulphacetamide succinylsulphathiazole, N1-N1-dimethyl-N4-sulphanilysulphanilamide, N4-benzyl-sulphanilamide and 2 - sulphanilamide - 4 - methylthiazole. Specified alkaline solubilizing agents are sodium bicarbonate, sodium citrate, potassium bicarbonate, potassium citrate, lithium citrate, calcium carbonate, dicalcium phosphate, tricalcium phosphate, disodium hydrogen phosphate, potassium dihydrogen phosphate or mixtures of two or more of these compounds.  The above ingredients may be incorporated in a chewing vehicle which may be a mixture of a gum base such as chicle, spruce gum or paraffin wax with corn syrup, flavouring, sucrose, cornstarch, and colouring matter.  Other permissible ingredients include glycerine, stearic acid or mineral oil.  The drug and the solubilizing agent may be distributed uniformly throughout the composition or may be disposed principally within a coated centre or within a layer of coating substance.  The Specification as open to inspection under Sect. 91 comprises also the employment of magnesium carbonate, hydroxide or oxide as the alkaline solubilizing agent.  This subject-matter does not appear in the Specification as accepted.
This study investigates the role of Stanniocalcin-1 (STC1) in melanoma progression, with a focus on its impact on metastasis, angiogenesis, and immune evasion. Systematic bioinformatics analysis revealed the potential influence of STC1 dysregulation on prognosis, immune cell infiltration, response to immune therapy, and cellular functions. In vitro assays were conducted to assess the proliferation, invasion, migration, and angiogenesis capabilities of A375 cells. In vivo experiments utilizing C57BL/6 J mice established a lung metastasis model using B16-F10 cells to evaluate macrophage infiltration and M2 polarization. A Transwell co-culture system was employed to explore the crosstalk between melanoma and macrophages. Molecular interactions among STC1, YAP, βPIX, and CCL2 are investigated using mass spectrometry, Co-Immunoprecipitation, Dual-Luciferase Reporter Assay, and Chromatin Immunoprecipitation experiments. STC1 was found to enhance lung metastasis by promoting the recruitment and polarization of M2 macrophages, thereby fostering an immunosuppressive microenvironment. Mechanistically, STC1 competes with YAP for binding to βPIX within the KER domain in melanoma cells, leading to YAP activation and subsequent CCL2 upregulation. CCL2-induced M2 macrophages secrete VEGFA, which enhances tumor vascularization and increases STC1 expression via the AKT signaling pathway in melanoma cells, establishing a pro-metastatic feedback loop. Notably, STC1-induced YAP activation increases PD-L1 expression, promoting immune evasion. Silencing STC1 enhances the efficacy of PD-1 immune checkpoint therapy in mice. This research elucidates STC1's role in melanoma metastasis and its complex interactions with tumor-associated macrophages, proposing STC1 as a potential therapeutic target for countering melanoma metastasis and augmenting the efficacy of PD-1 immunotherapy.
The invention discloses a coagulant for trauma hemostasis and in vitro blood clotting experiments and a preparation method of the coagulant, in particular a compound high-speed coagulant and the preparation method thereof. The compound high-speed coagulant comprises the following components in proportion: 1000ml of solvent water, 1000U-5000U of thrombin, 10-80g of thrombin stabilizing agent and 0.5-20g of excipient, wherein the solvent water can be replaced with solvent alcohol. The preparation method of the compound high-speed coagulant comprises the steps of: putting the thrombin and the excipient into a mixer, adding the solvent water or solvent alcohol until reaching the demand quantity, then adding the thrombin stabilizing according to the proportion, uniformly stirring for 10min, and sub-packaging after stirring uniformly. The coagulant can be used for controlling blood capillary and venous hemorrhage, and can also be used for an in vitro coagulation experiment, or can be applied to adhesion of skin and tissue grafts and making of a fixing agent. More remarkably, formed blood clots are stable without loosening, and the thrombin can be stored at normal temperature without inactivating. The coagulant has the characteristics of no adverse effects, wide application range and convenience for use.
Adult patients on the surgical intensive care unit (SICU), within 72 hours of admission to the SICU and until SICU discharge. Ultrasound Philips CX50, Frailty Index questionnaire and muscle strength tests.
This intervention has been tested in Australia with a small sample of teenagers, and it was associated with promising effects. The data collection consists of a digital questionnaire regarding sleep habits, insomnia, motivation, physical and mental health, and electronic media use; a selection of students will use the actigraph for a week. After the first week, the participants will be instructed to stop using screens 1 hour before their usual bedtime. After one week has passed, participants in the Technology restriction intervention will be asked to complete the previously mentioned questionnaires as well as questions about the intervention itself: its applicability, compliance, and whether or not they will continue to limit their screen time before bedtime. One year after the intervention, they will be asked to complete the same questionnaire as at baseline. A selection of students will also wear a wrist actigraph.
<P>PROBLEM TO BE SOLVED: To provide a functional food capable of decreasing a blood glucose level without causing side effects, and to provide a medicament.  <P>SOLUTION: Brassica campestris (Komatsuna) or its hybrid is used in decreasing blood glucose as the functional food or the medicament, because it decreases the blood glucose level or inhibits increase of the blood glucose level. A juice, a jelly or a dried pulverized powder is exemplified as the functional food. The juice is produced by pulverizing and mixing the Komatsuna or its hybrid together with a liquid and a bitterness softening material. The powder is produced by subjecting the Komatsuna or its hybrid to drying, such as solar drying, vacuum drying, and freeze-drying, and then to pulverizing. The Komatsuna or its hybrid is effectively decreased in its bitterness, by preliminarily treating it with hot water, etc., and then processing it to remove elements causing the bitterness.  <P>COPYRIGHT: (C)2004,JPO
FIELD: medicine. SUBSTANCE: described are new heterocyclic compounds of formula I:   wherein R 1  is carboxy or lower alkoxycarbonyl: R 2  is phenyl or lower alkylphenyl; R 3  is phenyl or lower alkylphenyl; A 1  is lower alkylene; A 2  is chemical bond or lower alkylene and Q is as defined in claims, or pharmaceutically acceptable salts thereof. Also described are intermediate compounds of formula II:   wherein R 2 ,R 3 ,A 2 ,-Q- are as defined above; R 4  is hydrogen or lower alkyl, or salts thereof. Invention is useful for preparing medicinals having inhibiting activity with respect to aggregation of thrombicytes and vasolidating activity. EFFECT: improved properties of the title compounds. 7 cl, 28 ex, 2 tbl